Athyrium Capital Management, LP
Follow13F filer, CIK 1728001, New York, NY
Athyrium Capital Management, LP reported $72,784,577 across 3 holdings for the quarter ended 2024-03-31, in a 13F-HR filed 2024-05-16.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-24-000137
- Period
- 2024-03-31
- Reported value
- $72.8M
- Holdings
- 3
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| PBYIreduced | -535,703 | -$2.84M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q1 2024
Share positions as resolved from 13F-HR 0001123292-24-000137, largest first. % of portfolio is the value over $72,784,577, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC | 10,929,762 | $12M | 16.52% | 0 | |||
| PBYIPUMA BIOTECHNOLOGY INC | 1,256,411 | $6.66M | 9.15% | -535,703 | Timeline |
Principal amounts
Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| OMEROS CORPOMEROS CORP NOTE 5.250% 2/1 | principal | 72,979,000 | $54.1M | 0 |
How Q1 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001123292-24-000137 | base | 2024-05-16 | acceptance time not in the bulk data set |